LEADER 03748nam 22006855 450 001 9910298294303321 005 20251215215818.0 010 $a3-319-18518-7 024 7 $a10.1007/978-3-319-18518-7 035 $a(CKB)3710000000402838 035 $a(EBL)2096709 035 $a(SSID)ssj0001500646 035 $a(PQKBManifestationID)11927799 035 $a(PQKBTitleCode)TC0001500646 035 $a(PQKBWorkID)11519884 035 $a(PQKB)11533867 035 $a(DE-He213)978-3-319-18518-7 035 $a(MiAaPQ)EBC2096709 035 $a(PPN)185489729 035 $a(EXLCZ)993710000000402838 100 $a20150422d2015 u| 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 14$aThe Future of HIV-1 Therapeutics $eResistance Is Futile? /$fedited by Bruce E. Torbett, David S. Goodsell, Douglas D. Richman 205 $a1st ed. 2015. 210 1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2015. 215 $a1 online resource (257 p.) 225 1 $aCurrent Topics in Microbiology and Immunology,$x0070-217X ;$v389 300 $aDescription based upon print version of record. 311 08$a3-319-18517-9 320 $aIncludes bibliographical references and index. 327 $aHIV Therapy ­ Looking Towards the Future -- Computational challenges of structure-based approaches applied to HIV -- Nucleocapsid Protein: A Desirable Target For Future Therapies Against HIV-1 -- HIV-1 integrase multimerization as a therapeutic target -- Targeting HIV transcription: The quest for a functional cure -- Targeting the HIV RNA Genome: High-Hanging Fruit Only Needs a Longer Ladder -- HIV-1 Gag: An Emerging Target for Antiretroviral Therapy -- The Triple Threat of HIV-1 Protease Inhibitors -- Illustrations of the HIV Life Cycle. 330 $aThis volume thoroughly covers HIV-1 antiretrovirals currently in clinical use, together with their advantages and limitations. HIV-1 inhibitor resistance is discussed in detail, and critical assessments as to what will be required of future antiretrovirals in order to halt viral replication, reduce viral resistance, and alter the state of viral latency are presented. Experts at the forefront of HIV-1 research provide overviews of approaches from the fields of virology, chemical biology and structural biology for obtaining small molecule inhibitors that target viral regulatory and structural components at multiple points in the viral lifecycle. The individual chapters will appeal to scientists and clinicians alike. 410 0$aCurrent Topics in Microbiology and Immunology,$x0070-217X ;$v389 606 $aDrug resistance 606 $aVirology 606 $aInfectious diseases 606 $aDrug Resistance$3https://scigraph.springernature.com/ontologies/product-market-codes/B16020 606 $aVirology$3https://scigraph.springernature.com/ontologies/product-market-codes/B22003 606 $aInfectious Diseases$3https://scigraph.springernature.com/ontologies/product-market-codes/H33096 615 0$aDrug resistance. 615 0$aVirology. 615 0$aInfectious diseases. 615 14$aDrug Resistance. 615 24$aVirology. 615 24$aInfectious Diseases. 676 $a610 676 $a616.9 676 $a616.9041 676 $a616.9101 702 $aTorbett$b Bruce E$g(Bruce Edward),$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aGoodsell$b David S.$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aRichman$b Douglas D.$4edt$4http://id.loc.gov/vocabulary/relators/edt 906 $aBOOK 912 $a9910298294303321 996 $aThe Future of HIV-1 Therapeutics$92494368 997 $aUNINA